Status:
COMPLETED
Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
National Multiple Sclerosis Society
Teva Neuroscience, Inc.
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-55 years
Brief Summary
The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce anti-inflammatory type II monocyte development during treatment of MS, and if these antigen presenting cells...
Eligibility Criteria
Inclusion
- Relapsing-remitting (RR) MS patients (McDonald criteria)
- Ages 18-55
- Males and females
- EDSS score ≤5
- No prior treatment with Copaxone
- Prior treatment with corticosteroids or interferon-beta (-1a or -1b) is acceptable, provided there is a washout period of at least one month
Exclusion
- Treatment with Tysabri, Novantrone or cyclophosphamide
- Treatment with other immunomodulatory therapies (e.g. imuran, mycophenolate or methotrexate)
- Primary-progressive (PP) and secondary-progressive (SP) multiple sclerosis
- Pregnancy
Key Trial Info
Start Date :
December 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00819195
Start Date
December 1 2008
End Date
September 1 2012
Last Update
October 8 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF Multiple Sclerosis Center
San Francisco, California, United States, 94143